SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine

SMS Pharmaceuticals Limited (SMS Pharma) (NSE: SMSPHARMA; BSE: 532815) is pleased to announce that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.

The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.

Shares of SMS Pharmaceuticals Limited was last trading in BSE at Rs. 274.00 as compared to the previous close of Rs. 271.80. The total number of shares traded during the day was 2730 in over 66 trades.

The stock hit an intraday high of Rs. 275.60 and intraday low of 271.50. The net turnover during the day was Rs. 747850.00.

Source : Equity Bulls

Keywords

SMSPharmaceuticals INE812G01025 VKTPharma USFDA Approval ReformulatedRanitidineTablets